Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹161 Cr
verified against source
Revenue YoY
57%
reported change
EBITDA
₹26.34 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Fredun Pharmaceuticals delivered a strong Q3 FY26 with revenue of ₹160.92 crore (+57% YoY), EBITDA of ₹26.34 crore (+99% YoY), and PAT of ₹10.48 crore (+96% YoY). EBITDA margin expanded 384 bps to 16%, driven by operating leverage and a favorable product mix shift toward high-margin new-age businesses (dermatics, pet care, nutritionals). Management reiterated its conservative guidance of 12-18% growth in the vintage business and 20-25% in new-age segments, targeting 51% revenue from new-age by FY29-30. The company sees no immediate need for funds and expects further margin expansion over the next 6-7 quarters as new brands achieve scale. Key risk: rapid expansion may strain working capital and finance costs, though management expects these to normalize.
Colored figures show movement against the previous available record.
Guidance to track
- Legacy business (exports, institutional, third-party) expected to grow 12-18% annually driven by 1,300-1,400 product registrations.
- Dermatics, pet care, and nutritionals expected to grow 20-25% annually; 51% of revenue by FY29-30.
- Operating leverage from high-margin new-age brands will drive profit growth over next 6-7 quarters.
- Current funds and internal cash flows sufficient; no equity raise planned in near term.
Risks flagged
- Finance costs rose due to working capital needs and new machinery loans; may pressure near-term profitability.
- Q4 typically has higher revenue but lower margins due to year-end discounts and schemes.
- New-age brands require state-wise launches and penetration; operational leverage may take longer than expected.
Key quotes
- Our conservative numbers are also robust growth. I don't want to be ever in a position where I'm underachieving a number.
- Anything over 5-6% is a great margin at the rate that we are growing.
- By 2029-2030, 51% of the business should be from the new age business.
Research modules